

1 **mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised**  
2 **patients.**

3 Elena Azzolini<sup>1,2,\*</sup>, Chiara Pozzi<sup>2,\*</sup>, Luca Germagnoli<sup>2</sup>, Bianca Oresta<sup>3</sup>, Nicola Carriglio<sup>3</sup>, Mariella Calleri<sup>3</sup>,  
4 Carlo Selmi<sup>1,2</sup>, Maria De Santis<sup>1,2</sup>, Silvia Finazzi<sup>2</sup>, Carmelo Carlo-Stella<sup>1,2</sup>, Alexia Bertuzzi<sup>2</sup>, Francesca  
5 Motta<sup>1,2</sup>, Angela Ceribelli<sup>1,2</sup>, Alberto Mantovani<sup>1,2,4</sup>, Fabrizio Bonelli<sup>3</sup> and Maria Rescigno<sup>1,2,#</sup>

6

7 <sup>1</sup>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20072 Pieve  
8 Emanuele, MI, Italy.

9 <sup>2</sup>IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, MI, Italy.

10 <sup>3</sup>DiaSorin S.p.A., Via Crescentino, I-13040 Saluggia, VC, Italy.

11 <sup>4</sup>The William Harvey Research Institute, Queen Mary University of London, London, UK

12

13 \*These authors contributed equally to the work

14

15

16 #Corresponding author

17 E-mail: [maria.rescigno@hunimed.eu](mailto:maria.rescigno@hunimed.eu)

18 Humanitas University

19 Via Rita Levi Montalcini, 4

20 20072 Pieve Emanuele (MI) Italy

21

22

23 **Abstract**

24 SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is  
25 progressively allowing to overcome the pandemic. Recent evidence has shown that response to vaccination  
26 in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the  
27 kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity,  
28 the CD4 and CD8 IFN- $\gamma$  T cell response in 328 subjects, including 131 immunocompromised individuals  
29 (cancer, rheumatologic, and hemodialysis patients), 160 healthcare workers (HCW) and 37 subjects older  
30 than 75 yo, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according  
31 to the type of treatment. We found that immunocompromised patients, depending on the type of treatment,  
32 poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a  
33 good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to  
34 HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-  
35 CoV-2 specific immune response than those who are vaccinated without prior infection.

36

37 **Running title**

38 COVID-19 vaccine booster in immunocompromised patients.

39

40 **Summary blurb (200 characters)**

41 Immunocompromised patients poorly respond to two doses of SARS-CoV-2 mRNA vaccines. However, an  
42 additional booster dose elicits a strong humoral and cellular immune response in these subjects.

43

44

45 **Introduction**

46 From December 2020 several anti-SARS-CoV-2 vaccines have been approved by the drug authority  
47 agencies for emergency use for the prevention and management of COVID-19. SARS-CoV-2 vaccination  
48 has proven to be effective in protecting against hospitalization and death in Israel (Haas et al, 2021), and,  
49 as shown by the COVID-19 vaccine breakthrough infection surveillance, also in the US even towards the  
50 Delta variant (Scobie et al, 2021). This indicates that vaccines can help control COVID-19 severity and  
51 the pandemic itself. Indeed, all of the vaccines approved so far have proven great efficacy in activating an  
52 immune response in healthy individuals (Abu Jabal et al, 2021; Arunachalam et al, 2021a; Arunachalam et  
53 al, 2021b; Dagan et al, 2021; Haas et al, 2021; Polack et al, 2020; Voysey et al, 2021; Walsh et al, 2020)  
54 and we and others have shown that one dose is sufficient in boosting the immune response in SARS-CoV-  
55 2 previously exposed subjects (Krammer et al, 2021a; Krammer et al, 2021b; Levi et al, 2021; Saadat et  
56 al, 2021; Sadoff et al, 2021; Samanovic et al, 2021). However, the ability of mRNA-based SARS-CoV-2  
57 vaccines to immunize primary or treatment-induced immunocompromised individuals has recently been  
58 questioned (Collier et al, 2021). In particular, patients with inflammatory bowel disease under infliximab  
59 treatment (Kennedy et al, 2021), patients who have received an allogeneic stem cell transplantation  
60 (Lafarge et al, 2022), cancer patients (Chung et al, 2021; Greenberger et al, 2021a; Greenberger et al,  
61 2021b; Ribas et al, 2021; Thakkar et al, 2021a; Thakkar et al, 2021b; Zeng et al, 2021), methotrexate  
62 treatment (Mahil et al, 2021), kidney transplant or hemodialysis (Danthu et al, 2021) (Bachelet et al, 2021)  
63 or multiple sclerosis (Apostolidis et al, 2021) have all demonstrated a reduced ability to mount an  
64 immune response, potentially adversely affecting protection offered by vaccines. However, studies in  
65 which a comprehensive comparative analysis of both humoral and cellular immune responses after a third  
66 dose of vaccine is lacking.

67 Indeed, the type of immunomodulatory treatment may have a differential effect according to the immune  
68 cell which is targeted. For instance, B-cell-directed therapies for hematological malignancies have been  
69 shown to affect the production of antibodies in response to SARS-CoV-2 vaccination due to B-cell  
70 depletion and/or disruption of the B-cell receptor signaling pathway while leaving unaltered the T cell  
71 response (Apostolidis et al, 2021) . This T cell response may compensate for the B cell response and may  
72 explain why anti-CD20 treated patients are still protected from COVID-19 (Huang et al, 2021). By

73 contrast, a general immune suppression due to drug treatments or the disease itself may affect both  
74 humoral and cellular responses. Hence, it is very important to evaluate the immunization status and the  
75 duration of response in immunocompromised patients undergoing SARS-CoV-2 vaccination and relate it  
76 to the type of treatment. Here, we compared the antibody production, CD4 and CD8 T cell response to the  
77 vaccine spike protein, as well as the neutralization potential of the antibody response in response to 2 or 3  
78 doses of SARS-CoV-2 vaccine in 328 subjects including healthcare workers (HCW), elderly subjects (>75  
79 yo) and immunocompromised patients with different pathologies either in hemodialysis, with cancer or  
80 rheumatological diseases in relation to their treatments.

81 We show that one of the major determinants of a successful immune response was the immune status,  
82 exposure to SARS-CoV-2 infection and type of treatment at the time of vaccination and that three doses of  
83 vaccine allowed achieve immunization even in immunocompromised individuals. However, as expected,  
84 anti-CD20 treatment impaired the development of an antibody response even after the third dose,  
85 suggesting that patients under this treatment should wait to receive the shots after interrupting the therapy.  
86 Patients under mycophenolate also respond poorly to vaccination, but interruption of therapy for just one  
87 week allows activation of the immune response. We also show that SARS-CoV-2 recovered  
88 immunocompromised individuals, similarly to healthy subjects (Krammer et al, 2021a; Krammer et al,  
89 2021b; Levi et al, 2021; Saadat et al, 2021; Sadoff et al, 2021; Samanovic et al, 2021), achieved a strong  
90 immune response, quicker than naïve subjects. Overall, this study highlights a need in a booster dose of  
91 vaccine in immunocompromised individuals, which should however consider their immune status and  
92 treatment. SARS-CoV-2 recovered patients instead, should be considered for the booster dose on an  
93 individual basis.

94

## 95 **Results**

### 96 **Clinical study**

97 In this observational study we analyzed the antibody production, the CD4 and CD8 T cell and the  
98 neutralizing antibody response to SARS-CoV-2 Spike protein in 328 subjects (Table 1) including  
99 healthcare workers (n= 160), elderly people >65 yo (n=37), and 131 immunocompromised patients with  
100 different pathologies including patients in hemodialysis (n=53), with cancer (n=30) or rheumatological

101 disease (n=48) at 2-4 months (T3) after the second dose of mRNA SARS-CoV-2 vaccination (Spikevax or  
102 Comirnaty). For immunocompromised patients we investigated the humoral and cellular immune response  
103 also at 2 weeks after the third (booster) dose (T4). In particular, 13 (44%) cancer patients, 31 (65%)  
104 patients with rheumatic disease and 44 (83%) patients in hemodialysis received the third dose. Moreover,  
105 for HCW and cancer patients we tested the kinetics of B and T cell development before vaccination (T0)  
106 at 21-28 days after the first dose (T1), 10-26 days after dose 2 (T2) and 2-4 months (T3) after the second  
107 dose (Fig. 1). 62 individuals had been previously exposed to SARS-CoV-2 (Table 1) and among these,  
108 only 6 out of 18 (33%) cancer patients, 1 out of 5 (20%) hemodialysis patients and 1 (100%) rheumatic  
109 disease patient received the third dose. The immune response was correlated with the type of pathology,  
110 the immune status and the treatment (Table 2).

111

#### 112 **SARS-CoV-2 naïve cancer patients treated with anti-CD20 fail to produce neutralizing antibodies.**

113 SARS-CoV-2 particle internalization is mediated by the binding of the trimeric form of the Spike protein  
114 with the ACE-2 receptor on host cells (Hoffmann et al, 2020). We chose to test the level of IgG antibodies  
115 directed to the trimeric form of Spike protein (LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG, DiaSorin) to have  
116 a better correlation with neutralizing antibodies. Nevertheless, we also tested the neutralization ability of  
117 the ensued antibodies via a surrogate test of Spike neutralization (cPass<sup>™</sup>, GenScript). As shown in Suppl.  
118 figure 1A, while the antibody response was induced in healthcare workers already after the first vaccine  
119 dose (T1) and reached a climax 10 days after the second dose (T2), it was either undetectable in cancer  
120 patients receiving anti-CD20 treatment (blue triangles, category 2) or reduced in patients receiving other  
121 drugs with low/medium impact to the immune system (orange and green/yellow triangles, categories 0 or  
122 1, respectively) at any time point between T0 and T3 (Fig. S1 A). In those patients that experienced an  
123 antibody response, the titers were much lower than those of the HCW suggesting that the amplitude of the  
124 antibody response was compromised. However, a booster dose of vaccine increased the antibody titers at  
125 levels similar to those of HCW, except for anti-CD20 treated cancer patients which remained undetectable  
126 (Fig. S1 A, T4). As the latter patients were discouraged to take a booster dose, we could test only three out  
127 of eight patients who insisted to receive it. Wherever detectable, the antibodies were neutralizing and were  
128 preserved at least four months after vaccination (T3), but only in those patients that were not in active

129 treatment at the time of vaccination (orange triangles, Fig. S1 A and Table 2). By contrast, the antibodies  
130 raised in HCW were all neutralizing (Fig. S1 A). Regarding SARS-CoV-2 previously exposed individuals,  
131 while nearly all HCW required one single dose to reach a very strong neutralizing antibody response, as  
132 we and other previously described (Krammer et al, 2021a; Krammer et al, 2021b; Levi et al, 2021; Saadat  
133 et al, 2021; Sadoff et al, 2021; Samanovic et al, 2021), SARS-CoV-2 naturally infected cancer patients  
134 required two doses to reach comparable neutralizing antibodies (Fig. S1 B), but almost all of them (16 out  
135 of 18) developed IgG antibody response, even if cancer patients were under active treatment at the time of  
136 vaccination (12 out of 18, Fig. S1 B and Table 2). In particular, ten were treated with drugs belonging to  
137 category 0, one with drug of category 1 (green triangles, Doxorubicin+Cisplatin) and one with anti-CD20  
138 (blue triangles, category 2) (Fig. S1 B and Table 2). A booster dose increased the amount of serum  
139 antibodies, particularly the neutralizing antibodies (Fig. S1 B, T4). The only naturally infected cancer  
140 patient under active anti-CD20 treatment did not increase antibodies even after the second dose (T2) (blue  
141 triangles, Fig. S1 B), and was advised to take a third dose after stopping the anti-CD20 treatment. A  
142 higher number of patients under this treatment is required to reach any conclusions.

143

#### 144 **SARS-CoV-2 naïve cancer patients treated with anti-CD20 may fail to activate T cell responses.**

145 The induction of a CD4 or CD8 T cell response is an additional arm of an effective vaccination. We thus  
146 evaluated the kinetic of anti-Spike T cell response activation in the two groups, by using specific CD4  
147 (Ag1) and CD4 plus CD8 (Ag2) T cell epitopes of the Spike protein. As shown in Suppl. figures 2A, we  
148 found that the T cell response (both to Ag1 and Ag2) was low in general in cancer patients and was  
149 observed only in three out of seven patients under anti-CD20 treatment at T2. Interestingly, the peripheral  
150 blood T cell response dropped three months after vaccination in a good proportion of subjects, including  
151 HCW, and in 9 out of 23 (Ag1) and in 5 out of 23 (Ag2) was below the threshold of positivity selected for  
152 this study. The booster dose to cancer patients re-elevated the T cell response to levels similar to those  
153 after the second dose but we did not observe further enhancement like that of the antibody response. Anti-  
154 CD20 treated patients that did not show a T cell response after the second dose, did not benefit from the  
155 booster dose (Fig. S2 A). As shown in Fig. S2 B, the T cell response was boosted in all of naturally

156 infected subjects at T2, regardless of being HCW or cancer patients with or without treatment (even anti-  
157 CD20) and it was high at 3-4 months after vaccination (T3) or at two weeks after the booster dose (T4).

158

159 **The immune response is compromised in a substantial proportion of patients in hemodialysis and in**  
160 **some rheumatologic patients but can be boosted by a third vaccine dose.**

161 Prompted by the intriguing results on cancer patients and the dependence of the immune response on the  
162 pharmacologic treatment, we evaluated whether other categories of immunocompromised patients  
163 displayed a compromised immune response to the vaccine and the outcome after a booster dose. Thus, we  
164 tested the trimeric antibody levels, their neutralization ability and T cell responses at 2-3 months from the  
165 second dose (T3) and at two weeks after the booster dose (T4) in patients with rheumatic diseases or in  
166 patients in hemodialysis. As patients in hemodialysis were older, we also included a group of elderly  
167 people ( $\geq 75$  yo) receiving the vaccine. As shown in Fig. 2 A, patients in hemodialysis had a significant  
168 reduction in trimeric antibody response at 3 months after the second dose of vaccine (T3) compared to  
169 health care workers ( $P < 0.0001$ ) and a drastic but not significant reduction versus older subjects. This  
170 response reflected also a significant reduction ( $P < 0.0001$ ) in the neutralizing ability of the antibodies (Fig.  
171 2 B) also in older subjects ( $P = 0.0026$ ). Rheumatic disease patients instead, as a group, had a reduction in  
172 IgG trimeric antibody response, which was not statistically significant, however, the neutralization  
173 potential was significantly reduced ( $P = 0.0499$ ) as compared to that of HCW individuals (Fig. 2, A and B).  
174 Notably, 4 patients had no neutralizing antibodies, although 2 of them had a positive antibody test. As  
175 shown in figure 2C and 2D, the T cell response (both Ag1 and Ag2) was significantly lower as compared  
176 to HCW in hemodialysis patients (Ag1,  $P = 0.0003$ ; Ag2,  $P = 0.0017$ ), but not in the other patients. When  
177 we analyzed the response at two weeks after the third dose (T4) we observed that all rheumatic patients  
178 and dialysis patients (except for one patient of each class) had increased the serum levels of antibodies  
179 ( $P < 0.0001$ ) which were also neutralizing except for three patients in hemodialysis, two of them having  
180 detectable trimeric antibodies (54.2 and 134 BAU/ml) which were not neutralizing (Fig. 2, A and B).  
181 However, although the T cell response was boosted, with a statistically significant increase only in dialysis  
182 patients (Ag1,  $P = 0.0014$ ; Ag2,  $P = 0.0015$ ), it remained below the limit of positivity set in this study for  
183 many patients (Fig. 2, C and D). Importantly, in Fig. S3A we reported INF- $\gamma$  basal levels, that may be

184 produced by other cell types (e.g. NK cells), and that we found to be below the cut-off threshold for the  
185 majority of samples. As observed also for cancer patients, previously exposed to SARS-CoV-2 patients  
186 displayed the highest levels of neutralizing antibodies which remained high also after the booster dose  
187 (Fig. S4, A and B). Moreover, the T cell responses remained higher in SARS-CoV-2 experienced patients  
188 than naïve HCW (Fig. S4, C and D; Fig. S3 A).

189

### 190 **The immune response depends on the type of treatment or immune status of the patients.**

191 Having observed a clear reduction in antibody levels in cancer or hemodialysis patients and in some  
192 rheumatologic disease patients, we analyzed whether the observed differences were linked to an immune  
193 depressed state induced by the treatment or by their disease. As described in the methods section, we  
194 classified the patients according to the type of treatment (cancer and rheumatic disease patients) or an  
195 immunoscore related to the disease for which the patients are in dialysis and their comorbidities. As  
196 shown in Fig. 3 A, S5A-B and S6A-B the type of treatment (no treatment or low (0), medium (1) or high  
197 (2) interference with the immune system) or the worsening of the immunoscore in hemodialysis patients  
198 (low (0), medium (1) or high (2) immune compromised) impacted on the profile of the immune response  
199 with a progressive reduction of both antibody levels (Fig. 3 A, S5A-B and S6A-B) and neutralization  
200 potential (Fig. 3 A). Interestingly, patients distributed quite homogenously in the three categories  
201 suggesting that their immune status, rather than the disease itself, was responsible for the impaired  
202 immune response. Particularly affected were patients belonging to category 2: patients in hemodialysis  
203 with an high immune compromised immunoscore, rheumatic disease patients treated with mycophenolate  
204 or methotrexate and cancer patients treated with anti-CD20 (Fig. 3A, blue crosses, yellow or pink circles  
205 and blue triangles, respectively; Fig. S5A-B and Fig. S6A-B). It should be noted that patients under  
206 methotrexate stopped treatment one week after getting vaccinated and indeed they all developed  
207 neutralizing antibodies (Fig. 3, A and B, pink circles). Interestingly, the third dose (T4) allowed patients in  
208 category 2 to achieve levels of antibodies similar to those in category 1 at 2 / 4 months after the second  
209 dose (T3) except for patients treated with anti-CD20 antibody (Fig. 3 A, blue triangles), one patient in  
210 hemodialysis (Fig. 3 A, blue cross) and one patient with mycophenolate (Fig. 3 A, yellow circle).  
211 Interestingly, the latter patient was advised to stop treatment for one week after vaccination, but did not



212 follow the advice. Patients in hemodialysis that were previously exposed to SARS-CoV-2 showed higher  
213 levels of IgG compared to those that were not infected, even after 6 months from the second dose, at the  
214 time of booster (Fig. S6, C and D). The booster dose increased significantly the neutralization ability of  
215 IgG in all the categories (Fig. 3 B). The T cell response also was affected particularly by the category of  
216 drugs with high interference with the immune system or by an immune compromised status (category 2),  
217 but differences with patients belonging to category 0 or 1 were not striking at T3. Interestingly, T cell  
218 response (both to Ag1 and Ag2) was statistically significantly boosted with a third dose only in category 2  
219 patients (Fig. 3, C and D). Moreover, in Fig. S3 B we reported INF- $\gamma$  basal levels, that we found to be  
220 below the cut-off threshold for the majority of samples. Interestingly, when analyzing the correlation  
221 between antibody levels and neutralization potential, we found that in the group of patients in the category  
222 2 (treated with drugs with high interference with the immune system or immune compromised patients)  
223 levels of trimeric antibody above 100 BAU/ml after the second dose are most likely to correspond to a  
224 positive neutralization test (>30%) (Fig. 4 A). The booster dose allowed most of the patients achieve a  
225 neutralizing antibody response, and it was confirmed that a level of antibodies above 100 BAU/ml  
226 correlated with a positive neutralization test (Fig. 4 B).

227

## 228 **Discussion**

229 Here we show that, upon vaccination, elderly subjects and patients under treatments that have little or no  
230 interference with the immune system develop an immune response which is slightly reduced but  
231 comparable to that of healthy individuals, while those immunosuppressed (with an immunoscore equal to  
232 2) or under immunosuppressive treatments are strongly impaired in the ability to activate an antibody  
233 response (i.e., cancer patients treated with anti-CD20 therapy or rheumatic disease patients under active  
234 treatment of mycophenolate). In some cases, the immune response is not initiated at all. However, a third  
235 booster dose allows to achieve levels of neutralizing antibodies similar to those of HCW after the second  
236 vaccine dose (T2) except for anti-CD20 treated cancer patients. By stratifying patients according to  
237 treatment, we show that anti-CD20 and mycophenolate are the drugs with the highest impact on the  
238 development of a correct immune response. By contrast, methotrexate which is associated with specific  
239 immune inhibitory drugs did not have a major impact on the immune response, but it has to be considered

240 that methotrexate therapy was stopped for one week after every dose of vaccine, whereas mycophenolate  
241 was not interrupted at the time of the first and second dose vaccination. This suggests that, wherever  
242 possible, treatment having an impact on the immune system should be interrupted or delayed in order to  
243 favor the development of an immune response. Indeed, at the administration of the third dose,  
244 mycophenolate was interrupted and this resulted in a proficient activation of the immune response. The  
245 patient who did not follow the advise of interrupting mycophenolate resulted in an undetectable antibody  
246 and T cell response even after the third booster dose, confirming that treatment should be stopped to favor  
247 the development of an immune response. Interestingly, as expected the antibody response to the trimeric  
248 form of Spike was undetectable in individuals under anti-CD20 treatment, and the situation did not change  
249 after the third dose. Interestingly also a patient that had interrupted anti-CD20 five months earlier still did  
250 not display antibodies to the Spike trimeric protein. This is in line with a recent report showing that  
251 patients with B-cell lymphoma (BCL) receiving B-cell-directed therapies should be vaccinated at least  
252 nine months from the last treatment to improve antibody titers (Ghione et al, 2021). By contrast the T cell  
253 response to AG1 and AG2 spike peptides was observed in three out of seven patients under anti-CD20  
254 treatment at T2. This to us was unexpected as it has been shown that anti-CD20 treated multiple sclerosis  
255 patients had a similar ability to induce T cells to the spike protein as healthy subjects (Apostolidis et al,  
256 2021). This suggests that cancer patients may have an additional impairment in inducing the T cell  
257 response which is probably unrelated to the active treatment. This makes cancer patients a very vulnerable  
258 category that needs further attention. It would be important to correlate the vaccine immune response to  
259 the stage of disease as the immune system may be depressed as a consequence of the immunosuppressive  
260 status generated by the cancer itself. Indeed, it has been shown that COVID-19 mortality was statistically  
261 significantly higher in cancer patients with an active disease (Pinato et al, 2020). Also, the immune status  
262 of the patients is strongly correlated with the ensued immune response as indicated by the impact of  
263 disease and immunoscore of patients in hemodialysis.

264 Regarding T cell analysis, we decided to test the T cell response by restimulating whole blood cells with  
265 specific peptides because we analyzed a population comprising immunocompromised individuals. Indeed,  
266 it is technically challenging to isolate T cells from immunocompromised individuals unless a large amount  
267 of blood is collected. It was already very difficult to recruit immunocompromised patients because of their

268 disease and treatments. In addition, many of them are continuously subjected to blood draws or treatments  
269 that require intravenous access and it was unlikely that they may participate in a protocol asking to donate  
270 more blood. This was a limitation along with the inability to measure the differences in T cell frequencies  
271 among participants. Moreover, we cannot exclude that the IFN- $\gamma$  measured after stimulation with SARS-  
272 COV-2 specific peptides could be produced also by other cell types (e.g. NK cells) and that the differences  
273 observed between groups could be accounted for by differences in T cell skewing related to the disease  
274 state and/or infection history. However, the finding that basal levels of IFN- $\gamma$  were below the threshold  
275 suggests that the observed production was due to peptide restimulation.

276 In conclusion, immunocompromised patients should be tested periodically to assess the development and  
277 status of an immune response and should be considered individually and on the basis of their active  
278 treatments with regards to a potential booster dose. Those that are not immunized should be prioritized to  
279 receive a booster dose of vaccine and be re-evaluated afterwards for effective immunization. However, the  
280 therapeutic schedule should be modulated (interrupted or delayed) to favor an immune response to the  
281 vaccine. Particular attention should be given to patients with antibody levels below 100 BAU/ml because  
282 these antibodies are unlikely to exert a neutralizing activity. A different scenario is observed in patients  
283 previously exposed to SARS-CoV-2. These patients reach maximal response after two doses of vaccine,  
284 still one subject under anti-CD20 treatment failed to activate an antibody response but developed a T cell  
285 response. More SARS-CoV-2 exposed patients should be tested with immunosuppressive treatments to  
286 draw conclusions.

287

## 288 **Materials and methods**

### 289 **Study design**

290 We tested the IgG antibody response, the CD4 and CD8 T cell activation and the neutralizing antibody  
291 response to SARS-CoV-2 spike protein developed after mRNA SARS-CoV-2 vaccination (Spikevax or  
292 Moderna mRNA-1273 – Comirnaty or BNT162b2 Pfizer-BioNTech) as a part of two observational studies  
293 approved by the Ethical Committee of Istituto Clinico Humanitas, in compliance with the Declaration of  
294 Helsinki principles. The studies were conducted at Istituto Clinico Humanitas and comprised a longitudinal  
295 sample collection, including healthcare workers (n=160) and cancer patients (n=30) and a cross-sectional

296 sample collection, including elderly subjects (n=37), patients with rheumatic diseases (n=48) and patients in  
297 hemodialysis (n=53). Immunocompromised patients received also a third dose (booster)  $\pm$  5 months after the  
298 second dose.

299 Analyzed time points were: the day of the first dose (T0), 21-28 days after the first dose (T1), 10-26 days  
300 after the second dose (T2), 2-4 months after the second dose (T3) and 2 weeks after the third dose (T4).

301 At each scheduled time point, as shown in Figure 1, serum and lithium-heparin whole blood samples were  
302 collected from enrolled individuals. Study inclusion criteria included a vaccination with an authorized  
303 COVID-19 vaccine (according to Italian regulation and guidelines), age of 18 years or greater, and  
304 willingness and ability to provide informed consent. Study exclusion criteria included lack of willingness and  
305 ability to provide informed consent, or a lack of properly collected and stored samples. Demographic and  
306 clinical information for healthy subjects (healthcare workers and elderly) and patients can be found in Tables  
307 1 and 2. Experiments were conducted in a blinded fashion with designated members of the clinical team,  
308 who did not run the assays, having access to the sample key until data were collected, at which point  
309 researchers of the team were unblinded. All individuals enrolled in the studies provided an informed consent  
310 as part of the protocols (CLI-PR-2102 and CLI-PR-2108;). These studies began in February 2021 (CLI-PR-  
311 2102) and June 2021 (CLI-PR-2108) and are continuing with participant's follow-up. Enrolled individuals  
312 did not receive compensation for their participation.

313

#### 314 **Patients and treatments**

315 Cancer and rheumatic disease patients were classified according to the type of treatment: no active treatment  
316 or low (category 0), medium (category 1) or high (category 2) interference with the immune system (Table  
317 2). In particular, drugs with low interference with the immune system (category 0) included: Tyrosine Kinase  
318 Inhibitor, TKI (Imatinib), EGFR TKI (Osimertinib), chemotherapy (Lenalidomide, Docetaxel, Gemcitabine,  
319 Nab-paclitaxel), hormone therapy, anti-HER2 agents (Pertuzumab, Trastuzumab), chemotherapy + anti-  
320 PDL1 (Carboplatin+etoposide+Atezolizumab) (for cancer patients) and ursodeoxycholic acid for rheumatic  
321 diseases patients; drugs with medium interference with the immune system (category 1) were: Doxorubicin  
322 (with Cisplatin or with Ifosfamide or present in ABVD) (for cancer patients) and anti-TNF Ab - Infliximab,  
323 Certolizumab, Adalimumab, Golimumab; TNF blocker - Etanercept; JAK1/2 inhibitor - Baricitinib;

324 CD80/CD86 blocker – Abatacept (for rheumatic diseases patients); immunosuppressive drugs (category 2)  
325 were rituximab, Obinutuzumab (for cancer patients), mycophenolate and methotrexate in combination with  
326 immune inhibitory drugs (for rheumatic disease patients). Treatment with methotrexate or Baricitinib  
327 (JAK1/2 inhibitor) was stopped one week after every dose of vaccine, whereas treatment with  
328 mycophenolate was stopped one week only after the third dose of vaccine.

329 Patients in hemodialysis were classified with an immunoscore related to the disease for which the patients  
330 are in dialysis and their comorbidities: low (category 0), medium (category 1) or high (category 2) immune  
331 compromised (Table 2).

332

### 333 **Detection of SARS-CoV-2 specific IgG antibodies**

334 Serum samples were tested using LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG (DiaSorin, Italy), a quantitative  
335 CE-marked assay for the detection of IgG antibodies recognizing the native trimeric Spike glycoprotein of  
336 SARS-CoV-2 (Bonelli et al, 2021). According to manufacturer's instruction for use, the presence of an  
337 immune response in vaccine recipients was 100.0% (95% CI 96.3–100.0%) in 102 samples collected after  
338  $\geq 21$  days from second dose. The levels of IgG antibodies were originally expressed in arbitrary units  
339 (AU/mL). Following the definition of the WHO International Standard for anti-SARS-CoV-2  
340 Immunoglobulin (NIBSC 20:136), the readout was updated and the assay currently calculates the levels of  
341 SARS-CoV-2 IgG antibodies in binding antibody units (BAU/mL) (Perkmann et al, 2021). Samples  $\geq 33.8$   
342 BAU/mL were considered positive. In Fig. S6, for the determination of IgG anti-SARS-CoV-2 in the serum  
343 of patients in hemodialysis the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin) was used (Bonelli et al,  
344 2020).

### 345 **SARS-CoV-2 neutralization assay**

346 Neutralization was assessed by ELISA with cPass<sup>™</sup> SARS-CoV-2 Neutralization Antibody Detection Kit  
347 (GenScript, China), a qualitative CE-marked assay for the detection of circulating neutralizing antibodies  
348 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with  
349 the ACE2 cell surface receptor (Tan et al, 2020). Samples were analyzed following manufacturer's  
350 instruction for use. Samples  $\geq 30\%$  signal inhibition were considered positive.

### 351 **Detection of SARS-CoV-2 specific cell-mediated immunity**

352 T cell-mediated responses were analyzed using QuantiFERON SARS-CoV-2 Research Use Only assay  
353 (QIAGEN, Germany), following manufacturer's instruction for use. We tested the IFN- $\gamma$  production before  
354 and after restimulation with SARS-CoV-2-specific antigens. Briefly, fresh whole blood samples were  
355 collected in lithium-heparin tubes and maintained at room temperature for no more than 16 hours from the  
356 time of collection. Each blood sample was transferred in a NIL-Tube (without antigens: this sample indicate  
357 the IFN- $\gamma$  basal level, before restimulation) and in two QuantiFERON SARS-CoV-2 blood collection tubes  
358 containing different cocktails of SARS-CoV-2-specific antigens (Ag1 and Ag2) and incubated at 37°C for  
359 16-24 h. Plasma samples retrieved after centrifugation at 2,700 x g at room temperature for 15 min were  
360 analyzed using LIAISON XL instrument (DiaSorin, Italy) for detection of IFN- $\gamma$ , according to the standard  
361 procedures recommended by the manufacturer. For this study, positive results were defined as  $\geq$   
362 0.25 IU/mL, after IFN- $\gamma$  basal level (NIL tube) was subtracted from Ag1 and Ag2 values. In Fig. S3 we  
363 showed the IFN- $\gamma$  basal level (IU/ml). We defined this tentative cut-off threshold based on previous  
364 experience with the QuantiFERON test but this is arbitrary as other studies have defined a lower cut off  
365 between 0.15 and 0.2 (Van Praet et al, 2021).

### 367 **Statistical analysis**

368 Data were analyzed for normal distribution (Shapiro-Wilk test) before any statistical analyses. Individual  
369 values are presented as spaghetti plots or as box plots showing the interquartile range, median, and  
370 minimum-to-maximum whiskers. The differences between matched time points were analyzed using the  
371 non-parametric Friedman test with Dunn's multiple comparisons test. The comparison of multiple groups  
372 was carried out using the non-parametric Kruskal-Wallis test followed by Dunn's multiple comparisons test.  
373 In order to gauge the correlation between IgG values in plasma (x variable) and the % of neutralization (y  
374 variable), a non-parametric Spearman's rank correlation test was performed. A probability value of  $P < 0.05$   
375 was considered significant. All statistics and reproducibility information are reported in the figure legends.  
376 Data analyses were carried out using GraphPad Prism version 8.

### 378 **Acknowledgments**

379 The reagents in this study were supplied by DiaSorin (Italy) and QuantiFERON SARS-CoV-2 tubes by  
380 QIAGEN (Germany). We acknowledge the full financial support of DiaSorin S.p.A. for CLI-PR-2102 and  
381 CLI-PR-2108 clinical trials. In DiaSorin we would like to thank Elisa Ghezzi, Clara Rossini, and Chiara  
382 Mauro for neutralization testing and Alice Bianchi for T cell response testing. We thank Jenny Howard,  
383 Francis Stieber, and Vladyslav Nikolayevskyy from QIAGEN for their scientific support during the study.  
384 We would like to thank all the employees and the patients that volunteered to participate to this study, all the  
385 vaccinating doctors, the nurses and personnel that collected the samples, the laboratory technicians that run  
386 the serological tests and Humanitas Operations Management and Customer Care that coordinated  
387 vaccinations and blood draws.

388

#### 389 **Author contributions**

390 All authors contributed to revise the manuscript for important intellectual content, were responsible for the  
391 decision to submit for publication, and approved the final submitted version of the manuscript. E.A and C.P  
392 contributed equally to the work. E.A. coordinated the recruitment and sampling of subjects (project  
393 administration) and participated in clinical study design; C.P.: contributed to project administration,  
394 performed data analysis and contributed to manuscript writing; L.G.: coordinated the laboratory analyses;  
395 DiaSorin: carried out the laboratory analyses; B.O., N.C. and M.C. participated in clinical study design,  
396 wrote the clinical protocols, contributed to project administration and to data analysis. C.S., M.DS., S.F.,  
397 C.C-S., A.B., F.M., A.C. recruited patients, reviewed and approved the manuscript. A.M.: conceptualization,  
398 reviewed and approved the manuscript; F.B. designed the clinical study and coordinated the teams; M.R.:  
399 conceived the study, analyzed the data and wrote the manuscript.

400

#### 401 **Conflict of interests**

402 F.B., M.C., N.C., and B.O. are employees of DiaSorin S.p.A., the manufacturer of the LIAISON SARS-  
403 CoV-2 TrimericS IgG test. Employees of DiaSorin participated in the study design, data collection and  
404 interpretation and in the preparation of the manuscript. M.R. participated to advisory boards and received  
405 support from Diasorin S.p.A. Other authors have declared that no conflict of interest exists.

406

407 **Funding**

408 This work was supported by DiaSorin S.p.A. and Ricerca Corrente (Ministero della Salute, to M.R and  
409 A.M.).

410

411

412 **References**

413

414 Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. (2021). Impact of age,  
415 ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2  
416 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to  
417 January 2021. *Euro Surveill* **26**:doi: 10.2807/1560-7917.ES.2021.26.6.2100096

418 Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza  
419 DA, Kadri JC, et al. (2021). Cellular and humoral immune responses following SARS-CoV-2  
420 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med* **27**:1990-2001.  
421 doi: 10.1038/s41591-021-01507-2

422 Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai  
423 L, et al. (2021a). Systems vaccinology of the BNT162b2 mRNA vaccine in humans. *Nature*  
424 **596**:410-416. doi: 10.1038/s41586-021-03791-x

425 Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV,  
426 et al. (2021b). Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. *Nature*  
427 **594**:253-258. doi: 10.1038/s41586-021-03530-2

428 Bachelet T, Bourdenx JP, Martinez C, Mucha S, Martin-Dupont P, Perier V, Pommereau A. (2021). Humoral  
429 response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2  
430 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times. *PLoS One*  
431 **16**:e0257646. doi: 10.1371/journal.pone.0257646

432 Bonelli F, Blocki FA, Bunnell T, Chu E, De La OA, Grenache DG, Marzucchi G, Montomoli E, Okoye L,  
433 Pallavicini L, et al. (2021). Evaluation of the automated LIAISON((R)) SARS-CoV-2 TrimericS IgG  
434 assay for the detection of circulating antibodies. *Clin Chem Lab Med* **59**:1463-1467. doi:  
435 10.1515/cclm-2021-0023

436 Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, Pallavicini L, Chinali A,  
437 Campisi D, et al. (2020). Clinical and Analytical Performance of an Automated Serological Test  
438 That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. *J Clin Microbiol*  
439 **58**:doi: 10.1128/jcm.01224-20

440 Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC,  
441 Boutemine SR, et al. (2021). Disease- and Therapy-Specific Impact on Humoral Immune Responses



442 to COVID-19 Vaccination in Hematologic Malignancies. *Blood Cancer Discov* **2**:568-576. doi:  
443 10.1158/2643-3230.Bcd-21-0139

444 Collier AY, Yu J, McMahan K, Liu J, Atyeo C, Ansel JL, Fricker ZP, Pavlakis M, Curry MP, Jacob-Dolan  
445 C, et al. (2021). COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. *J*  
446 *Infect Dis* doi: 10.1093/infdis/jiab569

447 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD.  
448 (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J*  
449 *Med* **384**:1412-1423. doi: 10.1056/NEJMoa2101765

450 Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, El Ouafi Z, Ponsard S, Berrahal I, Achard JM,  
451 et al. (2021). Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of  
452 Hemodialysis Patients and Kidney Transplant Recipients. *J Am Soc Nephrol* **32**:2153-2158. doi:  
453 10.1681/ASN.2021040490

454 Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, et  
455 al. (2021). Impaired humoral responses to COVID-19 vaccination in patients with lymphoma  
456 receiving B-cell-directed therapies. *Blood* **138**:811-814. doi: 10.1182/blood.2021012443

457 Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. (2021a). Anti-spike  
458 antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic  
459 malignancies. *Cancer Cell* **39**:1297-1299. doi: 10.1016/j.ccell.2021.09.001

460 Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. (2021b). Antibody  
461 response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell* **39**:1031-  
462 1033. doi: 10.1016/j.ccell.2021.07.012

463 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et  
464 al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections  
465 and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in  
466 Israel: an observational study using national surveillance data. *Lancet* **397**:1819-1829. doi:  
467 10.1016/S0140-6736(21)00947-8

468 Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu  
469 NH, Nitsche A, et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is  
470 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**:271-280.e278. doi:  
471 10.1016/j.cell.2020.02.052

472 Huang A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, Robinson J, Greenplate A, Porterfield F,  
473 Owoyemi O, et al. (2021). CD8 T cells compensate for impaired humoral immunity in COVID-19  
474 patients with hematologic cancer. *Res Sq* doi: 10.21203/rs.3.rs-162289/v1

475 Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF,  
476 Fraser A, et al. (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and  
477 ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. *Gut* **70**:1884-1893. doi:  
478 10.1136/gutjnl-2021-324789

479 Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermudez-Gonzalez MC,  
480 Bielak DA, Carreno JM, Chernet RL, et al. (2021a). Antibody Responses in Seropositive Persons  
481 after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**:1372-1374. doi:  
482 10.1056/NEJMc2101667

483 Krammer F, Srivastava K, Simon V. (2021b). Robust spike antibody responses and increased reactogenicity  
484 in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *medRxiv*  
485 2021.2001.2029.21250653. doi: 10.1101/2021.01.29.21250653

486 Lafarge A, Mabrouki A, Yvin E, Bredin S, Binois Y, Clere-Jehl R, Azoulay E. (2022). Coronavirus disease  
487 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in  
488 hematopoietic stem cell recipients. *Curr Opin Crit Care* **28**:83-89. doi:  
489 10.1097/mcc.0000000000000907

490 Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M. (2021). One dose of SARS-  
491 CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from  
492 symptomatic COVID-19. *J Clin Invest* **131**:doi: 10.1172/JCI149154

493 Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham  
494 C, Lechmere T, et al. (2021). The effect of methotrexate and targeted immunosuppression on  
495 humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.  
496 *Lancet Rheumatol* **3**:e627-e637. doi: 10.1016/S2665-9913(21)00212-5

497 Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, Wolzt M, Wagner OF,  
498 Binder CJ, Haslacher H. (2021). Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody  
499 Levels: a Head-to-Head Comparison of Five Quantitative Assays. *Microbiol Spectr* **9**:e0024721. doi:  
500 10.1128/Spectrum.00247-21

501 Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R,  
502 Segui E, et al. (2020). Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.  
503 *Cancer Discov* **10**:1465-1474. doi: 10.1158/2159-8290.Cd-20-0773

504 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED,  
505 Zerbini C, et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*  
506 *Med* **383**:2603-2615. doi: 10.1056/NEJMoa2034577

507 Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM. (2021). How to  
508 Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood*  
509 *Cancer Discov* **2**:562-567. doi: 10.1158/2643-3230.Bcd-21-0166

510 Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. (2021).  
511 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers  
512 Previously Infected With SARS-CoV-2. *JAMA* **325**:1467-1469. doi: 10.1001/jama.2021.3341

513 Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W,  
514 Leroux-Roels I, et al. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19  
515 Vaccine. *N Engl J Med* **384**:1824-1835. doi: 10.1056/NEJMoa2034201

516 Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz  
517 G, Ali M, Koralov SB, et al. (2021). Poor antigen-specific responses to the second BNT162b2  
518 mRNA vaccine dose in SARS-CoV-2-experienced individuals. *medRxiv* 2021.2002.2007.21251311.  
519 doi: 10.1101/2021.02.07.21251311

520 Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, Bertolino D, Blythe D, Brady S,  
521 Cadwell B, et al. (2021). Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths,  
522 by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. *MMWR Morb Mortal Wkly Rep*  
523 **70**:1284-1290. doi: 10.15585/mmwr.mm7037e1

524 Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, et al. (2020). A  
525 SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-  
526 spike protein-protein interaction. *Nat Biotechnol* **38**:1073-1078. doi: 10.1038/s41587-020-0631-z

527 Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica  
528 RA, et al. (2021a). Seroconversion rates following COVID-19 vaccination among patients with  
529 cancer. *Cancer Cell* **39**:1081-1090.e1082. doi: 10.1016/j.ccell.2021.06.002

530 Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY,  
531 et al. (2021b). Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease  
532 and association with anticancer therapy. *Nat Cancer* **2**:392-399. doi: 10.1038/s43018-021-00191-y

533 Van Praet JT, Vandecasteele S, De Roo A, De Vriese AS, Reynders M. (2021). Humoral and Cellular  
534 Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing  
535 Home Residents. *Clin Infect Dis* **73**:2145-2147. doi: 10.1093/cid/ciab300

536 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas  
537 SL, Bhorat QE, et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)  
538 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South  
539 Africa, and the UK. *Lancet* **397**:99-111. doi: 10.1016/S0140-6736(20)32661-1

540 Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan  
541 MJ, Bailey R, et al. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine  
542 Candidates. *N Engl J Med* **383**:2439-2450. doi: 10.1056/NEJMoa2027906

543 Zeng C, Evans JP, Reisinger S, Woyach J, Liscynsky C, Boghdadly ZE, Rubinstein MP, Chakravarthy K,  
544 Saif L, Oltz EM, et al. (2021). Impaired neutralizing antibody response to COVID-19 mRNA  
545 vaccines in cancer patients. *Cell Biosci* **11**:197. doi: 10.1186/s13578-021-00713-2

546

547

548 **Figures Legends**

549

550 **Figure 1. Experimental design.**

551 IgG antibody response, the CD4 and CD8 T cell activation (Ag1 and Ag2) and the neutralizing antibody  
552 response to SARS-CoV-2 spike protein developed after mRNA SARS-CoV-2 vaccination (Spikevax or  
553 mRNA-1273, Moderna - Comirnaty or BNT162b2, Pfizer-BioNTech) were analyzed as a part of two  
554 observational studies approved by the Ethical Committee of Istituto Clinico Humanitas, in compliance with  
555 the Declaration of Helsinki principles. The studies were conducted at Istituto Clinico Humanitas and  
556 comprises a longitudinal sample collection, including healthcare workers (n=160) and cancer patients (n=30)  
557 and a cross-sectional sample collection, including elderly subjects (n=37), patients with rheumatic diseases  
558 (n=48) and patients in hemodialysis (n=53). Immunocompromised patients received a third dose (booster) ±  
559 5 months after the second dose. Analyzed time points were: the day of the first dose (T0), 21-28 days after  
560 the first dose (T1), 10-26 days after the second dose (T2), 2-4 months after the second dose (T3) and 2 weeks  
561 after the third dose (T4).

562

563 **Figure 2. The immune response is compromised in a substantial proportion of naïve patients in**  
564 **hemodialysis and in some naïve rheumatologic patients but can be boosted by a third vaccine dose.**

565 IgG antibody response (A), its neutralizing activity (B) and anti-spike T cell response activation, by using  
566 specific CD4 (Ag1, C) and CD4 plus CD8 (Ag2, D) T cell epitopes of the spike protein were measured in  
567 serum and plasma of vaccinated naïve health care workers (HCW, n=104), elderly people ≥75 yo (n=35),  
568 cancer patients (n=9), patients with rheumatic diseases (n=47) or patients in hemodialysis (n=48) at 2-4  
569 months after second dose (black, T3) and in serum and plasma of cancer patients (n=7), patients with  
570 rheumatic diseases (n=30) or patients in hemodialysis (n=43) 2 weeks after the booster dose (red, T4). As a  
571 control, we indicated values of IgGs, their neutralizing activity and anti-spike T cell response activation of  
572 vaccinated naïve health care workers (HCW, n=119) at 10 days after the second dose (T2). The box plots  
573 show the interquartile range, the horizontal lines show the median values, and the whiskers indicate the  
574 minimum-to-maximum range. Each dot corresponds to an individual subject. *P* values were determined  
575 using 2-tailed Kruskal-Wallis test with Dunn's multiple comparisons post test. *P* values refer to HCW T3

576 when there are no connecting lines. Positivity was based on: anti-spike IgG  $\geq$  33.8 BAU/mL (LIAISON  
577 SARS-CoV-2 TrimericS IgG); neutralization (Neu)  $\geq$  30% (cPass SARS-CoV-2 Neutralization Antibody  
578 Detection Kit), and T cell response  $\geq$  0.25 IU/mL for either Ag1 or Ag2 (QuantiFERON SARS-CoV-2  
579 assay).

580

581 **Figure 3. The immune response depends on the type of treatment or immune status of the patients.**

582 IgG antibody response (A), its neutralizing activity (B) and anti-spike T cell response activation, by using  
583 specific CD4 (Ag1, C) and CD4 plus CD8 (Ag2, D) T cell epitopes of the spike protein were measured in  
584 serum and plasma of vaccinated naïve patients with cancer (n=9), rheumatic diseases (n=47) or patients in  
585 hemodialysis (n=48) at 2-4 months after second dose (T3) and 2 weeks after the booster dose (T4). Cancer  
586 and rheumatic disease patients were classified according to the type of treatment: no active treatment or low  
587 (category 0), medium (category 1) or high (category 2) interference with the immune system, whereas  
588 patients in hemodialysis were classified with an immunoscore related to the disease for which the patients  
589 are in dialysis and their comorbidities: low (category 0), medium (category 1) or high (category 2) immune  
590 compromised. The distribution of patients in each category and the type of treatment are indicated in the  
591 legend. Samples  $\geq$  33.8 BAU/mL (IgG plasma levels) or  $\geq$  30% signal inhibition (neutralization) and T cell  
592 response  $\geq$  0.25 IU/mL for either Ag1 or Ag2 were considered positive (dotted black lines). The box plots  
593 show the interquartile range, the horizontal lines show the median values, and the whiskers indicate the  
594 minimum-to-maximum range. Each dot corresponds to an individual subject. *P* values were determined  
595 using 2-tailed Kruskal-Wallis test with Dunn's multiple comparisons post test. *P* values are reported.

596

597 **Figure 4. Correlation between antibody levels and neutralization potential.** Correlation between IgG  
598 values in serum (x variable) and the % of neutralization (y variable) was performed in each category of  
599 immunocompromised patients at T3 (0, n=23; 1, n=43; 2, n=38) (A) and at T4 (0, n=18; 1, n=30; 2, n=32)  
600 (B). A non-parametric Spearman's rank correlation test was performed. Samples  $\geq$  33.8 BAU/mL (IgG  
601 plasma levels) or  $\geq$  30% signal inhibition (neutralization, dotted black line) were considered positive. Log  
602 scale on x axis.

603


604 **Table 1. Cohort design and summary statistics.** Demographic and clinical information, including age, sex,  
605 SARS-CoV-2 infection and vaccine type.

606

607 **Table 2. Immunocompromised patients and treatments.** Clinical information and treatments of patients  
608 with cancer (hematologic or solid cancer), rheumatic disease or undergoing hemodialysis. Classification in  
609 categories (0, 1, 2) is reported. Cancer and rheumatic disease patients were classified according to the type of  
610 treatment at the time of vaccination: no active treatment or low (0), medium (1) or high (2) interference with  
611 the immune system. Patients in hemodialysis were classified with an immunoscore related to the disease for  
612 which the patients are in dialysis and their comorbidities: low (0), medium (1) or high (2) immune  
613 compromised.

614

615




Assay	Cohort
IgG	HCW (n=160) Cancer patients (n=30)
Neutralization	HCW (n=33) Cancer patients (n=30)
Ag1	
Ag2	


Assay	Cohort
IgG	HCW (n=160) Cancer patients (n=30) Rheumatic disease patients (n=48) Elderly ≥75 yo (n=37) Hemodialysis patients (n=53)
Neutralization	
Ag1	
Ag2	

Assay	Cohort
IgG	Cancer patients (n=13) Rheumatic disease patients (n=31) Hemodialysis patients (n=44)
Neutralization	
Ag1	
Ag2	


A




B



C




D







A





B






C






D



A



B



**Table 1**

	HCW	Elderly $\geq 75$	Cancer patients	Rheumatic disease patients	Dialysis patients
Subjects (n)	160	37	30	48	53
Sex					
Female	108 (67.5%)	20 (54.1%)	14 (46.7%)	29 (60.4%)	19 (35.8%)
Male	52 (32.5%)	17 (45.9%)	16 (53.3%)	19 (39.6%)	34 (64.2%)
Age					
Mean (Min - Max)	30.23 (19-77)	79.03 (75-87)	54.9 (35-79)	54.92 (25-78)	73.28 (50-93)
SARS-CoV-2 naturally infected					
No	124 (77.5%)	35 (94.6%)	12 (40%)	47 (97.9%)	48 (90.6%)
Yes	36 (22.5%)	2 (5.4%)	18 (60%)	1 (2.1%)	5 (9.4%)
Vaccine Type					
Comirnaty Pfizer	160 (100%)	37 (100%)	30 (100%)	0 (0%)	53 (100%)
Spikevax Moderna	0 (0%)	0 (0%)	0 (0%)	48 (100%)	0 (0%)

**Table 2**

		CATEGORY	0	1	2	
		Subjects (n)	No active treatment	Low	Medium	High
<b>Hematologic cancer patients</b>		13	2	2	1	8
SARS-CoV-2 naturally infected						
	No	8	0	0	1	7
	Yes	5	2	2	0	1
<b>Tumor type</b>						
	Diffuse Large B cell Lymphoma (DLBCL)	4	1	0	0	3
	Hodgkin Lymphoma (HL)	1	0	0	1	0
	Follicular lymphoma (FL)	5	0	0	0	5
	Multiple Myeloma (MM)	1	0	1	0	0
	Chronic lymphocytic leukemia (CLL)	1	1	0	0	0
	Chronic myeloid leukemia (CML)	1	0	1	0	0
<b>Solid cancer patients</b>		17	6	8	3	0
SARS-CoV-2 naturally infected						
	No	4	2	0	2	0
	Yes	13	4	8	1	0
<b>Tumor type</b>						
	Breast Cancer	7	2	5	0	0
	Lung Cancer	2	0	2	0	0
	Sarcoma	6	4	0	2	0
	Pancreatic Cancer	1	0	1	0	0
	Testicular cancer	1	1	0	0	0
<b>Rheumatic disease patients</b>		48	5	4	26	13
SARS-CoV-2 naturally infected						
	No	47	5	3	26	13
	Yes	1	0	1	0	0
<b>Diagnosis</b>						
	Autoimmune hepatitis (AIH)	2	2	0	0	0
Psoriatic arthritis /Spondyloarthritis/Ankylosing spondylitis (PA/SpA/AS)		18	0	0	17	1
	Rheumatoid arthritis (RA)	12	1	0	8	3
Primary biliary cholangitis (PBC)		5	1	4	0	0
	Sclerosing cholangitis (SC)	1	0	0	1	0
Dermatomyositis (DM)		2	0	0	0	2
Systemic lupus erythematosus (SLE)		1	0	0	0	1
Primary Sjögren's syndrome (pSS)		1	0	0	0	1
Systemic sclerosis (SSc)		6	1	0	0	5
<b>Dialysis patients</b>		53	0	15	16	22
SARS-CoV-2 naturally infected						
	No	48	0	12	16	20
	Yes	5	0	3	0	2
<b>Acute kidney injury (AKI) causes</b>						
	ANCA-associated vasculitis	1	0	0	0	1

Chronic Glomerulonephritis (CGN)	6	0	1	2	3
Glomerulopathy after liver transplantation	1	0	0	0	1
Nephrolithiasis	1	0	1	0	0
Nephropathy	5	0	0	3	2
Nephrosclerosis	33	0	9	11	13
Non-Hodgkin lymphoma (NHL)	1	0	0	0	1
Polycystic kidney disease (PKD)	5	0	4	0	1